The U.S. Food and Drug Administration intends to add firm warnings about suicidal behavior on the labels of 11 epilepsy medications, as indicated by files posted on the organization’s Web site.

The FDA will require companies to bring the drugs’ labels up to date, in order to include black-box warnings, the most severe warnings the agency releases. The proposition will be assessed by external consultants at a conference held on Thursday in Beltsville, Md.

The board of outside specialists is due to review the dangers produced by the drugs that treat epilepsy, a disease indicated by convulsions that can cause unconscious movement or unintentional actions.

Transactions of epilepsy medications, regularly prescribed in order to remedy psychiatric disorders, surpassed $10.2 billion in the United States last year. The FDA’s investigation upon almost 200 studies discovered that 0.43 percent of the patients who were taking the drugs committed suicide or at least had such intentions, compared with 0.24 percent of patients on a placebo. Drug manufacturers and examiners argued the findings, saying that it is erroneous to mingle statistics made upon medicines that have different roles.

The group of outside advisers to the agency is programmed to decide how to publicize the risks that were first disclosed by the FDA in a January 31 notification to healthcare suppliers.

The major epilepsy drugs sellers were J&J’s Topamax and Glaxo’s Lamictal, each holding 21 percent of the market, as said by the research firm IMS Health Inc. Other well-known products included in the FDA’s analysis are Pfizer Inc.’s Neurontin and Lyrica, Meda AB’s Felbatol, UCB SA’s Keppra, sold by several drug manufacturers.